Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Xilio TherapeuticsXLO +1.05%32 Debt-to-Equity is 0.09 as of Mar. 2026, which is 53% below its 10-year median of 0.19. GuruFocus rates XLO with a GF Score™ of 32/100. The stock has 2 warning signs investors should review. Among 966 Biotechnology companies, Xilio Therapeutics ranks better than 62.22% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Xilio Therapeutics's Debt-to-Equity or its related term are showing as below:
XLO'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.9 Med: 0.19 Max: 1.07
Current: 0.09
During the past 7 years, the highest Debt-to-Equity Ratio of Xilio Therapeutics was 1.07. The lowest was -0.90. And the median was 0.19.
XLO's Debt-to-Equity is ranked better than 62.22% of 966
companies
in the Biotechnology industry
Industry Median: 0.16
vs XLO: 0.09
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Xilio Therapeutics Debt-to-Equity Related Terms
Xilio Therapeutics Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Xilio Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XLO vs FLNA, BSEM, BOLD: Debt-to-Equity Comparison
For the Biotechnology subindustry, Xilio Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xilio Therapeutics Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xilio Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Xilio Therapeutics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xilio Therapeutics (XLO) has a Debt-to-Equity of 0.09 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Xilio Therapeutics and its competitors. This is 53% below median its historical median of 0.19. According to the industry distribution chart, Xilio Therapeutics ranks #365 out of 966 companies in the Biotechnology industry, placing it in the top 37.8%.
Is Xilio Therapeutics' Debt-to-Equity too high?
Xilio Therapeutics' current Debt-to-Equity of 0.09 is 53% below median its 10-year median of 0.19. The Biotechnology industry median Debt-to-Equity is 0.16. Xilio Therapeutics' value of 0.09 is 43.8% below this industry median. Based on the distribution chart, Xilio Therapeutics ranks #365 out of 966 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Xilio Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Xilio Therapeutics' Debt-to-Equity compare to FLNA and BSEM?
According to the Biotechnology industry distribution chart, Xilio Therapeutics ranks #365 out of 966 companies for Debt-to-Equity. This puts Xilio Therapeutics in the upper half of its industry. The industry median Debt-to-Equity is 0.16. Xilio Therapeutics' value of 0.09 is 43.8% below this benchmark. While the company's 10-year median is 0.19 vs. the industry median of 0.16, Xilio Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xilio Therapeutics's current Debt-to-Equity of 0.09 is 43.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Xilio Therapeutics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xilio Therapeutics's current Debt-to-Equity is 0.09, which is 53% below median its own 10-year median of 0.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xilio Therapeutics stock overvalued right now?
Xilio Therapeutics (XLO) has a current Debt-to-Equity of 0.09. The current Debt-to-Equity is 0.09, which is 53% below median its 10-year median of 0.19 and 43.8% below the Biotechnology industry median of 0.16. Xilio Therapeutics' overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Xilio Therapeutics (XLO), the current Debt-to-Equity is 0.09 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.
32GF Score
Get the complete analysis for XLO
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XLO has been successfully added to your 
